Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Estrogen Receptor Beta (ERβ) Expression in Different Subtypes of Malignant Pleural Mesothelioma

Author(s): Guitti Pourdowlat, Maryam Parvizi, Shogher Boyadjian, Masoud Shamaei* and Mihan Pourabdollah*

Volume 18, Issue 1, 2022

Published on: 01 February, 2022

Page: [50 - 56] Pages: 7

DOI: 10.2174/1573398X18666220111144745

Price: $65

Abstract

Background: Estrogen receptor beta (ERβ) is a potential target for cancer therapy as a tumor suppressor. Malignant pleural mesothelioma (MPM) is a rare but fatal cancer. This study tries to estimate the incidence of ERβ expression in the various subtypes of MPM tumors.

Methods and Materials: In a retrospective study performed at a pulmonary tertiary referral hospital, formalin-fixed paraffin-embedded human tissues of 46 definitive MPM were evaluated for expression of ERβ by immunohistochemistry.

Results: ERβ was detected in 14 cases (30.4%) out of the total 46 patients with a mean age of 58.08±11.59 SD, including 33 (71.7%) males. There was no statistically significant difference in patients with positive ERβ staining versus negative cases in age and sex (P >0.05). MPM subtypes included 36 (78.2%) cases of epithelioid mesothelioma, 3 (6.5%) cases of sarcomatoid, 5 (10.8%) cases of biphasic, and 2 (4.3%) cases of desmoplastic subtype. ERβ expression was observed only in epithelioid (11 of total 36 cases) and biphasic (3 of total 5 cases) tumors. There was no significant difference in the incidence of ERβ expression in different subtypes of malignant pleural mesothelioma. Statistical analysis shows a significant difference in the expression of ERβ in the epithelioid subtype (with a more favorable prognosis) versus non-epithelioid subtypes (with poor prognosis, including sarcomatoid, desmoplastic, and biphasic) (P = 0.024).

Discussion and Conclusion: Considering the higher proportion of the epithelioid type of MPM with ERβ expression, this highlights the role of ERβ in target therapy of MPM tumor, especially in the epithelioid subtype with a more favorable prognosis. A better understanding of the pathology of mesothelioma will eventually contribute to the development of therapies beyond the existing therapeutic platform.

Keywords: Estrogen receptor beta, malignant mesothelioma, immunohistochemistry, lung, breast, renal.

« Previous Next »
Graphical Abstract

[1]
Nicolini F, Bocchini M, Bronte G, et al. Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future. Front Oncol 2020; 9: 1519.
[http://dx.doi.org/10.3389/fonc.2019.01519] [PMID: 32039010]
[2]
Geltner C, Errhalt P, Baumgartner B, et al. Austrian Mesothelioma Interest Group (AMIG). Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr 2016; 128(17-18): 611-7.
[http://dx.doi.org/10.1007/s00508-016-1080-z] [PMID: 27619223]
[3]
Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007; 109(7): 1432-8.
[http://dx.doi.org/10.1002/cncr.22526] [PMID: 17315168]
[4]
Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003; 9(3): 206-17.
[http://dx.doi.org/10.1179/oeh.2003.9.3.206] [PMID: 12967156]
[5]
Henderson D, Whitaker D, Shilkin K. The differential diagnosis of malignant mesothelioma: a practical approach to diagnosis during life. In: Malignant mesothelioma. New York: Hemisphere 1992; p. 184.
[6]
Attanoos RL, Gibbs AR. Primary malignant gonadal mesotheliomas and asbestos. Histopathology 2000; 37(2): 150-9.
[http://dx.doi.org/10.1046/j.1365-2559.2000.00942.x] [PMID: 10931239]
[7]
Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol 1996; 20(9): 1067-80.
[http://dx.doi.org/10.1097/00000478-199609000-00004] [PMID: 8764743]
[8]
Organization W.H. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). In: International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans. 2012; p. 100.
[9]
Sayan M, Mossman BT. Erionite and Asbestos in the Pathogenesis of Human Malignant Mesotheliomas.The Molecular Basis of Human Cancer. Germany: Springer 2017; pp. 287-95.
[http://dx.doi.org/10.1007/978-1-59745-458-2_18]
[10]
Testa JR. Asbestos and Mesothelioma. Germany: Springer 2017.
[http://dx.doi.org/10.1007/978-3-319-53560-9]
[11]
Świątkowska B, Szubert Z, Sobala W, Szeszenia-Dąbrowska N. Predictors of lung cancer among former asbestos-exposed workers. Lung Cancer 2015; 89(3): 243-8.
[http://dx.doi.org/10.1016/j.lungcan.2015.06.013] [PMID: 26126784]
[12]
Visonà SD, Capella S, Bodini S, et al. Inorganic fiber lung burden in subjects with occupational and/or anthropogenic environmental asbestos exposure in broni (Pavia, northern Italy): an sem-eds study on autoptic samples. Int J Environ Res Public Health 2021; 18(4): 2053.
[http://dx.doi.org/10.3390/ijerph18042053] [PMID: 33669843]
[13]
Macfarlane E, Benke G, Sim MR, Fritschi L. OccIDEAS: an innovative tool to assess past asbestos exposure in the Australian Mesothelioma Registry. Saf Health Work 2012; 3(1): 71-6.
[http://dx.doi.org/10.5491/SHAW.2012.3.1.71] [PMID: 22953234]
[14]
Organization WH. Asbestos: elimination of asbestos-related diseases. In: Fact sheet no 343. Paris: WHO 2010.
[15]
British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62(Suppl. 2): ii1-ii19.
[PMID: 17965072]
[16]
Aerts JG, Delahaye M, van der Kwast TH, Davidson B, Hoogsteden HC, van Meerbeeck JP. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol 2006; 34(8): 523-7.
[http://dx.doi.org/10.1002/dc.20486] [PMID: 16850492]
[17]
Comin CE, de Klerk NH, Henderson DW. Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis? Ultrastruct Pathol 1997; 21(4): 315-20.
[http://dx.doi.org/10.3109/01913129709021929] [PMID: 9205996]
[18]
Hammar SP. Neoplasms of the pleura.Dail and Hammar’s pulmonary pathology. Germany: Springer 2008; pp. 558-734.
[http://dx.doi.org/10.1007/978-0-387-72114-9_12]
[19]
Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133(8): 1317-31.
[http://dx.doi.org/10.5858/133.8.1317] [PMID: 19653732]
[20]
van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis 2013; 5(6): E254-307.
[PMID: 24416529]
[21]
Comin CE, Novelli L, Boddi V, Paglierani M, Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001; 32(5): 529-36.
[http://dx.doi.org/10.1053/hupa.2001.24329] [PMID: 11381372]
[22]
Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001; 125(10): 1316-20.
[http://dx.doi.org/10.5858/2001-125-1316-IAONVC] [PMID: 11570906]
[23]
Wick MR, Moran CA, Mills SE, Suster S. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma. Curr Opin Pulm Med 2001; 7(4): 187-92.
[http://dx.doi.org/10.1097/00063198-200107000-00004] [PMID: 11470972]
[24]
Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002; 15(1): 6-10.
[http://dx.doi.org/10.1038/modpathol.3880483] [PMID: 11796835]
[25]
Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003; 27(2): 150-8.
[http://dx.doi.org/10.1097/00000478-200302000-00002] [PMID: 12548160]
[26]
Granville LA, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol 2005; 13(1): 75-9.
[http://dx.doi.org/10.1097/00129039-200503000-00012] [PMID: 15722797]
[27]
Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 2006; 34(12): 801-6.
[http://dx.doi.org/10.1002/dc.20556] [PMID: 17115439]
[28]
Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19(4): 514-23.
[http://dx.doi.org/10.1038/modpathol.3800534] [PMID: 16554731]
[29]
Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007; 109(5): 933-8.
[http://dx.doi.org/10.1002/cncr.22477] [PMID: 17279584]
[30]
Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010; 38(4): 264-9.
[http://dx.doi.org/10.1002/dc.21340] [PMID: 20146302]
[31]
Davidson B. Prognostic factors in malignant pleural mesothelioma. Hum Pathol 2015; 46(6): 789-804.
[http://dx.doi.org/10.1016/j.humpath.2015.02.006] [PMID: 25824607]
[32]
Pinton G, Brunelli E, Murer B, et al. Estrogen receptor-β affects the prognosis of human malignant mesothelioma. Cancer Res 2009; 69(11): 4598-604.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4523] [PMID: 19487281]
[33]
Pinton G, Thomas W, Bellini P, et al. Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One 2010; 5(11): e14110.
[http://dx.doi.org/10.1371/journal.pone.0014110] [PMID: 21124760]
[34]
Mersereau JE, Levy N, Staub RE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist. Mol Cell Endocrinol 2008; 283(1-2): 49-57.
[http://dx.doi.org/10.1016/j.mce.2007.11.020] [PMID: 18177995]
[35]
Yakimchuk K, Jondal M, Okret S. Estrogen receptor α and β in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol 2013; 375(1-2): 121-9.
[http://dx.doi.org/10.1016/j.mce.2013.05.016] [PMID: 23707618]
[36]
Pinton G, Manente AG, Daga A, et al. Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. Mol Cancer 2014; 13(1): 227.
[http://dx.doi.org/10.1186/1476-4598-13-227] [PMID: 25277603]
[37]
Song X, Pan Z-Z. Estrogen receptor-beta agonist diarylpropionitrile counteracts the estrogenic activity of estrogen receptor-alpha agonist propylpyrazole triol in the mammary gland of ovariectomized sprague dawley rats. J Steroid Biochem Mol Biol 2012; 130(1-2): 26-35.
[http://dx.doi.org/10.1016/j.jsbmb.2011.12.018] [PMID: 22266284]
[38]
Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) α activity by ERbeta in the uterus. Endocrinology 2003; 144(7): 3159-66.
[http://dx.doi.org/10.1210/en.2002-0143] [PMID: 12810572]
[39]
Gompel A, Plu-Bureau G. Ovarian cancer and hormone replacement therapy. Lancet 2007; 370(9591): 932-3.
[http://dx.doi.org/10.1016/S0140-6736(07)61436-6] [PMID: 17869627]
[40]
Ellem SJ, Risbridger GP. Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 2007; 7(8): 621-7.
[http://dx.doi.org/10.1038/nrc2174] [PMID: 17611544]
[41]
Gallo D, De Stefano I, Grazia Prisco M, Scambia G, Ferrandina G. Estrogen receptor beta in cancer: an attractive target for therapy. Curr Pharm Des 2012; 18(19): 2734-57.
[http://dx.doi.org/10.2174/138161212800626139] [PMID: 22390760]
[42]
Travis WD, et al. World health organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. 2004; 10: 179-84.
[43]
Steele JP. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 2005; 19(6): 1041-1052, vi. [vi.].
[http://dx.doi.org/10.1016/j.hoc.2005.09.009] [PMID: 16325122]
[44]
Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002; 188(1-2): 125-40.
[http://dx.doi.org/10.1016/S0303-7207(01)00750-X] [PMID: 11911952]
[45]
Jennings CJ, O’Grady A, Cummins R, et al. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma. J Thorac Oncol 2012; 7(1): 243-8.
[http://dx.doi.org/10.1097/JTO.0b013e31822f6544] [PMID: 22011668]
[46]
Odisio EG, et al. Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.Seminars in Ultrasound, CT and MRI. Elsevier 2017.
[http://dx.doi.org/10.1053/j.sult.2017.07.006]
[47]
Pouryaghoub G, et al. Exposure to asbestos in patients with malignant mesothelioma in Iran. Tehran Univ Med J 2014; 72(2)
[48]
Rusch VW, Giroux D, Kennedy C, et al. IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012; 7(11): 1631-9.
[http://dx.doi.org/10.1097/JTO.0b013e31826915f1] [PMID: 23070243]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy